3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Colorectal Neoplasms
402
Rectal Neoplasms
151
Colonic Neoplasms
148
Pancreatic Neoplasms
111
Stomach Neoplasms
106
Neoplasm Metastasis
87
Neoplasms
74
Esophageal Neoplasms
59
Small Cell Lung Carcinoma
44
Neuroblastoma
42
Lung Neoplasms
42
Glioblastoma
38
Carcinoma, Non-Small-Cell Lung
37
Brain Neoplasms
33
Esophageal Squamous Cell Carcinoma
32
Unspecified Adult Solid Tumor, Protocol Specific
31
Glioma
31
Breast Neoplasms
28
Central Nervous System Neoplasms
27
Adenocarcinoma Of Esophagus
27
Sarcoma
26
Gliosarcoma
22
Astrocytoma
22
Rhabdomyosarcoma
21
Sarcoma, Ewing
18
Adenocarcinoma
18
Gastrointestinal Neoplasms
17
Oligodendroglioma
16
Recurrence
13
Medulloblastoma
13
Interventions
Metformin
2
Leuprolide
2
Collagenases
2
Clomiphene
2
tremelimumab
1
durvalumab
1
Temozolomide
1
Streptozocin
1
Spironolactone
1
Specimen Handling
1
Radiosurgery
1
Radiation
1
Propofol
1
Prednisone
1
Plasma Exchange
1
Nivolumab
1
Midazolam
1
Mercaptopurine
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Ipilimumab
1
Infliximab
1
Immunoglobulins
1
High-Throughput Nucleotide Sequencing
1
Fentanyl
1
FANG vaccine
1
Cyclophosphamide
1
Clomipramine
1
Carmustine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Rare Diseases
×
Irinotecan
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts